Neurizon Therapeutics Limited, a clinical-stage biotech company dedicated to advancing innovative treatments for ...

Sangamo Therapeutics, Inc.’s SGMO share price has surged by 10.12%, which has investors questioning if this is right time to ...

Sangamo Therapeutics, Inc.’s SGMO share price has dipped by 5.89%, which has investors questioning if this is right time to ...

The number of people who have the gene that causes Huntington's disease in Northern Scotland has been accurately counted for ...

AMT-130 is administered through magnetic resonance imaging-guided, convection-enhanced stereotactic neurosurgical delivery into the striatum.

Qure's long-term success hinges on overcoming regulatory and logistical challenges. See why I rate QURE stock a hold.

Northern Scotland has one of the highest rates of Huntington’s disease globally, according to new research from the University of Aberdeen. For the first time in 35 years, scientists have ...

Dublin, April 18, 2025 (GLOBE NEWSWIRE) -- The "Huntington's Disease Treatment Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" has been added to ResearchAndMarkets ...

Qure's AMT-130 shows 80% Huntington's Disease progression slowing. Click to read more on QURE's financially strong, advancing ...

uniQure's AMT-130 receives Breakthrough Therapy designation from FDA for Huntington's disease, based on promising clinical trial data. uniQure N.V. announced that the U.S. FDA has granted ...

The US Food and Drug Administration (FDA) has awarded breakthrough therapy designation to uniQure's AMT-130 for treating ...